As Li et al. summarized, there are five potential therapeutic strategies that involve survivin: inhibitors disrupting survivin interactions with its partner proteins; inhibitors affecting survivin homodimerization; inhibitors decreasing survivin gene transcription; inhibitors inducing survivin mRNA degradation; and survivin-based cancer immunotherapy [95]. This evidence concerns the gene BIRC5 and cancer.